Transforming patients’

lives through science™

We are leaders in innovation and scientific
breakthroughs with a long legacy of bringing
life-saving medicines to people around the world.

Our research and development efforts are focused

on life-altering conditions like cancer and diseases
of the heart, immune system, and blood.
Headquartered in New York City, we are one of
the world's largest pharmaceutical companies
who have been fortunate to consistently rank
on the Fortune 500 list of companies in the US.

We’ve been providing medication to patients in

India for more than a decade. Our team in India
is dedicated to researching, developing and
delivering life-saving and life-enhancing
innovative medicines.

02
Global Company Highlights
for 2022
The company was
formed in Consistently ranks
Founded in on the

1858 1989 Fortune

as the Squibb Corporation through the merger of
Bristol-Myers Company &
Squibb Corporation
500
Total revenue of

$46.2
The company employs
more than
7%
30,000 billion in FY 2022
Consistent with prior year or,
In-Line Brand
YoY% growth
people globally an increase of 3% when excluding
foreign exchange

87% Potential for +

GAAP EPS1
New Product
Portfolio* YoY% growth $25B+ $2.95
of non-risk adjusted
Potential for risk-adjusted revenues in 2030
sales of $10-$13B revenues in 2025

18 $9.5B 9
approvals in the US, invested in research new products launched
EU and Japan and development over ~3 years^

+
GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of ($0.24) per share
for the full year 2022. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges
resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of
third-party intellectual property rights.

*New Product Portfolio includes Reblozyl® (luspatercept-aamt), Inrebic® (fedratinib), Onureg® (azacitidine tablets),
Zeposia® (ozanimod), Breyanzi® (lisocabtagene maraleucel), Abecma® (idecabtagene vicleucel), Opdualag®
(relatlimab plus nivolumab), Camzyos® (mavacamten) and SotyktyuTM (deucravacitinib).
^
Portfolio achievements from 2H 2019-2022.

03
Awards & Recognition
Passionate and precise, we aim to bring life-saving medicines to people around
the world. And we work together with compassion to improve outcomes for the
patients who need us most.

We are proud recipients of a diverse range of awards that honor our global company's
dedication to everything from innovation to safety, from working moms to military
vets. Each one is a tribute to our colleagues and our single vision—transforming
patients’ lives through science.

2023 2021
Best Places to Work Best Places to Work for LGBTQ Equality
By BioSpace By Human Rights Campaign Foundations

2022
World’s Most Admired Company
By Fortune

2020
World’s Best Workplaces
By GPTW
Best Place to Work Disability Inclusion Working Mother 100 Best Companies
By Disability Equality Index By Working Mother
Best Workplaces for Innovators
By Fast Company

Best Places To Work

2016
By Fortune CEO Cancer Gold Standard
By CEO Roundtable on Cancer
100 Best Companies
By Seramount
Top Companies for Executive Women
By Seramount
2015
Best Biotechnology Product
Energy Start Awards
(Partner of the Year Sustained Excellence) By Prix Galien USA 2015 Award
By U.S. EPA Energy

04
Opportunities To Learn More
• Learn more about BMS and take the opportunity to view our latest
Annual Report.
• Global Patient Week is an essential part of our culture — it unifies us and reignites
our passion to do more for our patients. As the first biopharma to set aside time
solely focused on the individuals we are working for each and every day, Global
Patient Week is a pinnacle of our year-round vision to transform patients’ lives
through science. Learn about Global Patient Week.
• Search and apply for roles.
• Keep in touch about the latest news and opportunities that match your interests.
• Read career stories from our team members and learn more about our culture.

05
Bristol-Myers Squibb Company is an Equal Opportunity Employer – M/F/Veteran/Disability Sexual Orientation/Gender Identity.
© 2023 Bristol-Myers Squibb Company. All rights reserved. 4/23